लोड हो रहा है...
IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report
BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE). As the number of cases under treatment with ICIs increases, new types of ch...
में बचाया:
| में प्रकाशित: | BMC Pulm Med |
|---|---|
| मुख्य लेखकों: | , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
BioMed Central
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7183131/ https://ncbi.nlm.nih.gov/pubmed/32334571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-020-1150-x |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|